Subscription database. Conference scout. KOL network. Due-diligence consultant. Deal facilitator. We do all five — calibrated to one geography of your choice — under a single fixed retainer.
What's inside the retainer
Every retainer covers all six. Frequency, format, and depth are tuned to your geography and BD priorities.
Continuous in-region scanning across regulatory filings, conference floors, technology-transfer offices, broker networks, and proprietary BD relationships — all calibrated to your stated therapeutic priorities.
Every shortlisted asset receives a structured evaluation dossier covering clinical development, regulatory pathway, IP landscape, competitive positioning, commercial potential, and strategic fit. Scoring is transparent, with confidence levels stated.
Daily tracking of approvals, trial starts, deal announcements, pricing decisions, and market-access shifts in your competitive zone. Distilled into weekly flashes and expanded in monthly intelligence reports.
On-site presence at four region-relevant congresses per year. Pre-event target lists, one-on-one meeting facilitation, same-day flash reports, post-event opportunity briefs.
Beyond intelligence, we actively introduce and facilitate. Initial outreach, due-diligence material exchange, term-sheet discussion support, ongoing liaison through to heads of agreement.
A dedicated dashboard on the ForesightRx platform with deal pipeline tracking, contact management, asset watchlists, and an AI-powered copilot that answers natural-language questions with sourced and cited evidence.
Every shortlisted asset is scored across these dimensions in every dossier — same yardstick, every time.
Cadence
Predictable rhythm. Designed to keep your BD team continuously informed without information overload.
Pick your corridor
Every market has its own regulators, conferences, broker networks, and signal channels. We build the in-region intelligence stack so you don't have to.
Why retainer, not subscription
Subscription databases rarely cover regional regulators (NMPA, PMDA, MFDS, CDSCO), local trial registries, or vernacular biotech channels in sufficient depth. Our team monitors them daily.
Subscriptions don't do on-site coverage; or they charge premium per-event fees. Four region-relevant conferences are included in your retainer.
A subscription stops at delivering data. We make introductions, coordinate diligence, and facilitate term-sheet discussions through to heads of agreement.
Fixed quarterly retainer. No per-query fees. No surprise charges for an extra dossier or a sudden conference run.
Fixed quarterly retainer. No per-query fees. No surprise dossier or extra-conference charges. Conferences, platform access, and the AI research copilot are all included. Request a tailored proposal →
Case Study · What this looks like in practice
Chinese biotechs filed 35% of all global IND applications in 2024. Cross-border out-licensing from China reached $14.4 B in upfront and milestone value — a 68% year-on-year jump (BioCentury, January 2025). By the time these assets surface in English-language databases, the window has often already closed. Below is the eight-source intelligence stack we run for a Greater China retainer — the same architecture we replicate for any other corridor.
Daily monitoring of new IND applications, clinical trial registrations, NDA submissions, and approval decisions.
On-site presence at four major China-focused conferences per year with structured one-on-one meeting programmes.
Composition-of-matter, formulation, and method-of-use claims scanned in original Chinese, not English translations.
Biotech WeChat groups, Zhihu medical forums, Chinese-language industry newsletters — deal signals weeks before English coverage.
Direct outreach to technology-transfer offices at Tsinghua, Peking, Fudan, Zhejiang, Shanghai Jiao Tong, and others.
Established relationships with Chinese biotech BD executives, licensing intermediaries, and deal brokers in Shanghai, Beijing, Suzhou, Guangzhou.
Inova, Cortellis, Biotechgate — monitored continuously for newly listed Chinese assets seeking out-licensing partners.
200+ Chinese biotech companies and 500+ China-origin assets already tracked in our living database.
Pre-event target lists. On-site one-on-one meeting facilitation. Same-day flash reports. Post-event opportunity briefs within five business days.
700+ delegates from 500+ companies across 30 countries (ChinaBio, 2025).
Asia's largest pharma exhibition: 110,000+ professionals from 150+ countries (CPHI, 2026).
Modelled after JPM Healthcare. Multinational pharma + global I-banks + 1,000+ Chinese innovators.
Curated by BioCentury, BayHelix, and McKinsey. Senior BD + innovation leadership.
We run the equivalent in-region programme for any other corridor. Japan via PMDA + BioJapan + JBA networks. Korea via MFDS + Bio Korea + K-PIC. India via CDSCO + IPC + India BioForum. EU via EMA + BIO-Europe + Swiss Biotech Day. Same retainer architecture. Different sources, conferences, and BD relationships — calibrated to where the deals actually happen.
Optional Add-Ons
The retainer scope is comprehensive. These additional services can be commissioned at any time during the engagement.
Tell us where you're sourcing from. We will scope a 12-month programme calibrated to that corridor and your therapeutic priorities.
Request a tailored proposalNo commitment. No sales pitch. Honest fit assessment.